Therma Bright Provides Update on Venowave's Permanent CPT/HCPCS Codes and United States Distribution Partners
Therma Bright Provides Update on Venowave's Permanent CPT/HCPCS Codes and United States Distribution Partners
Toronto, Ontario--(Newsfile Corp. - August 4, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced today that it expects a final decision regarding the issuance of the unique permanent Current Procedural Terminology (CPT) / Healthcare Common Procedure Coding System (HCPCS) codes to be released by the Centers for Medicare and Medicaid Services (CMS) within the coming weeks.
安大略省多倫多-(Newsfile Corp.-2023年8月4日)-Therma Bright Inc.(TSXV：THRM)(OTCQB：TBRIF)(以下簡稱“Therma”或“公司”)今天宣佈，預計聯盟醫療保險和醫療補助服務中心(CMS)將在未來幾周內發佈關於發佈唯一永久當前程式術語(CPT)/醫療保健通用程式編碼系統(HCPCS)代碼的最終決定。
Furthermore, the Company would also like to announce that it is growing its U.S. distribution partner network and encouraging continued use of the (9) temporary CPT and HCPCS codes. Specifically, the Company's distributor in Texas has already tapped into its doctor network and is processing the temporary code applicants for reimbursement. The Texas distributor believes that these temporary codes, with established reimbursement amounts, will help them accelerate adoption and purchases of the Venowave solution through its large doctor network.
此外，該公司還想宣佈，它正在擴大其美國分銷合作夥伴網路，並鼓勵繼續使用臨時CPT和HCPCS代碼。具體地說，該公司在德克薩斯州的分銷商已經接入了其醫生網路，並正在處理申請報銷的臨時代碼申請者。這家德克薩斯州分銷商認為，這些臨時代碼以及確定的報銷金額將幫助他們通過其龐大的醫生網路加快Venowave解決方案的採用和購買。
In addition to having the South-Central region covered with the Texas distributor, Therma Bright is in the final stages of securing a Northeast distributor out of Connecticut and is in early discussions with a Medicare Advantage group in Florida; the Southeast region partner. Both organizations have vast doctor networks to sell the Venowave, which will greatly expand sales and distribution of the innovative circulatory device.
除了讓德克薩斯州的分銷商覆蓋中南部地區外，Therma Bright還處於從康涅狄格州獲得東北分銷商的最後階段，並正在與佛羅裡達州的聯盟醫療保險優勢集團(Medicare Advantage Group)進行早期談判，後者是東南部地區的合作夥伴。這兩個組織都有龐大的醫生網路來銷售Venowave，這將極大地擴大這種創新迴圈設備的銷售和分銷。
"We're pleased with our current distribution partners' efforts in selling the Venowave through our nine (9) temporary CPT and HCPCS codes," shared Rob Fia, CEO of Therma Bright. "In fact, one of our potential new distribution partners is a Medicare Advantage healthcare provider, who offer bundled plans to patients who can only use doctors within this network. Medicare Advantage groups can purchase directly from the Company, which effectively is dealing directly with the payor. We believe this will help secure more Venowave sales with greater distribution for the Company."
Therma Bright公司首席執行官羅布·菲亞說：“我們對目前的分銷夥伴通過我們的九(9)個臨時CPT和HCPCS代碼銷售Venowave的努力感到高興。事實上，我們潛在的新分銷合作夥伴之一是Medicare Advantage醫療保健提供商，他們向只能使用該網路中的醫生的患者提供捆綁計劃。Medicare Advantage集團可以直接從公司購買，公司實際上是直接與付款人打交道。我們相信這將有助於確保更多的Venowave銷售，為公司提供更大的分銷。
Medicare Advantage is a Medicare-approved plan from a private company that offers an alternative to Original Medicare for senior citizens health and drug coverage. These "bundled" plans include Part A, Part B, and usually Part D. In most cases, seniors can only use doctors who are in the Medicare Advantage Plan network. In fact, Medicare Advantage plans cover everything Original Medicare covers plus more, so if a senior citizen wants dental, vision and/or fitness benefits, a Medicare Advantage plan often is the right choice.
Medicare Advantage是一傢俬人公司批准的Medicare計劃，為老年人提供替代原有Medicare的健康和藥物保險。這些“捆綁”計劃包括A部分、B部分和通常的D部分。在大多數情況下，老年人只能使用聯盟醫療保險優勢計劃網路中的醫生。事實上，Medicare Advantage計劃涵蓋原始Medicare涵蓋的所有內容以及更多，因此如果老年人想要牙科、視力和/或健身福利，Medicare Advantage計劃通常是正確的選擇。
The Company looks forward to providing more information as it becomes available on the unique permanent CPT and HCPCS codes and on expanding its distribution partners across the U.S. for its Venowave device.
該公司期待著在獲得唯一的永久CPT和HCPCS代碼以及擴大其Venowave設備在美國各地的分銷夥伴方面提供更多資訊。
About Therma Bright Inc.
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: .
關於Therma Bright Inc.
Therma Bright是一家領先的專有診斷和醫療設備技術的開發商和合作夥伴，致力於為消費者和醫療專業人員提供高質量的創新解決方案，以應對當今一些最重要的醫療和保健挑戰。Therma Bright Inc.在多倫多證券交易所(TSXV：THRM)(場外交易市場代碼：TBRIF)(紐約證券交易所代碼：JNX)交易。參觀：。
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Therma Bright Inc.
羅布·菲亞，首席執行官
郵箱：rfia@thermabright.com
Follow us on Twitter
關注我們的推特
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as the commercialization and sales of Venowave and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
前瞻性陳述
本新聞稿中的某些陳述構成“前瞻性”陳述。這些陳述涉及未來的事件，如新聞稿中描述的Venowave和相關技術的商業化和銷售。所有這些陳述都涉及大量已知和未知的風險、不確定因素和其他因素，這些風險、不確定因素和其他因素可能導致實際結果與這些前瞻性陳述明示或暗示的結果大不相同。前瞻性陳述涉及重大風險和不確定因素，不應被解讀為對未來業績或結果的保證，也不一定是能否實現此類結果的準確跡象。由於幾個因素和風險，實際結果可能與預期大不相同。儘管本新聞稿中包含的前瞻性陳述是基於公司管理層認為本新聞稿發佈之日的合理假設，但公司不能向投資者保證實際結果將與這些前瞻性陳述一致。本新聞稿中包含的前瞻性陳述是自本新聞稿發佈之日起作出的，除非適用的證券法規另有要求，否則公司不會因為新資訊、未來事件或其他原因而更新或修改任何前瞻性陳述的意圖或義務。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
多倫多證券交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。